SNGX News and Press, Soligenix Inc. From 06/10/21

Soligenix (SNGX) jumps 13% premarket after receiving a Pediatric Investigation Plan ((PIP)) waiver from the EMA for HyBryte (SGX301 or hypericin), which has recently and successfully concluded a Phase 3 study for the treatment of early stage cutaneous T-cell lymphoma ((CTCL)). ...

Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency PR Newswire PRINCETON, N.J. , June 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biophar...

Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program PR Newswire PRINCETON, N.J. , June 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biop...

Company Connecting the Dots for Final FDA Approval New York, New York--(Newsfile Corp. - June 3, 2021) - PCG Digital -- When Soligenix (NASDAQ: SNGX) updated its NDA rollout plan, the market quickly reacted. While the timeline was adjusted, the big picture and ultimate end game remain the s...

Soligenix (SNGX) announces that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Producing Synthetic Hypericin".The allowed claims are directed to unique, proprietary methods to produce a novel, highly purified form of synthetic hypericin, and are sim...

Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire PRINCETON, N.J. , May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (...

Soligenix (SNGX): Q1 GAAP EPS of -$0.06 beats by $0.05.Revenue of $0.1M (-88.9% Y/Y) misses by $0.3M.Press Release For further details see: Soligenix EPS beats by $0.05, misses on revenue

Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results PR Newswire PRINCETON, N.J. , May 17, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing ...

Gainers: Protagenic Therapeutics (PTIX) +67%.Obalon Therapeutics (OBLN) +57%.Precipio (PRPO) +35%.Cue Biopharma (CUE) +31%.SemiLEDs (LEDS) +28%.CKX Lands (CKX) +27%.Tecnoglass (TGLS) +24%.Soliton (SOLY) +24%.Party City Holdco (PRTY) +19%.uCloudlink (UCL) +16%.Losers: Rekor...

Soligenix (SNGX) is trading sharply lower after the company announced its decision not to pursue a rolling submission for its marketing application of HyBryte (SGX301) in the treatment of cutaneous T-cell lymphoma ((CTCL)).After discussions with the FDA, “the company decided ...